Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ravindra Sarode

Blood Banking & Transfusion Medicine Dallas, TX Medical Doctor

NPI 1265493688 CMS profile 103153

5323 Harry Hines Blvd, Dallas, TX 75390

Open in the dashboard

General payments

$79,775

100 records reported · program years 2019–2025

Research payments

$64,543

Paid to them · 31 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,250,267 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ravindra Sarode of Dallas, TX is reported in the CMS Open Payments database as having received $79,775 across 100 general payments and $64,543 in research payments paid to them. Separately, studies naming them as principal investigator received $1,250,267 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Blood Banking & Transfusion Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,816 26
2024 General $14,922 12
2024 Research $21,917 13
2023 General $26,632 19
2023 Research $20,719 8
2022 General $13,611 20
2022 Research $20,107 9
2021 General $3,899 7
2021 Research $1,800 1
2020 General $11,710 9
2019 General $3,184 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ravindra Sarode
  • Blood Banking & Transfusion Medicine median
  • Middle half of Blood Banking & Transfusion Medicine
  • National median

In program year 2025, general payments to Ravindra Sarode were reported at $5,816. Among 109 Blood Banking & Transfusion Medicine profiles paid that year, the median was $146 and the middle half received between $63 and $2,018.

Show as a table
Year Ravindra Sarode Blood Banking & Transfusion Medicine median Middle half National median
2019 $3,184 $125 $48–$2,312 $163
2020 $11,710 $759 $90–$20,131 $114
2021 $3,899 $1,000 $95–$13,211 $132
2022 $13,611 $260 $66–$4,567 $149
2023 $26,632 $201 $62–$2,687 $160
2024 $14,922 $150 $42–$2,468 $164
2025 $5,816 $146 $63–$2,018 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Argenx US, Inc. $28,487 4 payments
  2. CSL Behring $17,847 4 payments
  3. Octapharma USA, Inc. $6,691 15 payments
  4. Genzyme Corporation $6,355 10 payments
  5. Novo Nordisk Inc $5,380 4 payments
  6. Merck Sharp & Dohme Corporation $5,260 8 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $2,500 1 payment
  8. Cerus Corporation $2,358 7 payments
  9. Abbott Laboratories $1,945 19 payments
  10. Siemens Medical Solutions USA, Inc. $725 7 payments
  11. Other $2,227 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $41,865 16 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,847 4 payments
  3. Food and Beverage $7,245 66 payments
  4. Grant $5,135 3 payments
  5. Honoraria $4,500 2 payments
  6. Travel and Lodging $3,162 8 payments
  7. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. VYVGART $28,487 4 payments
  2. Kcentra $17,847 4 payments
  3. VYVGART Hytrulo $12,812 2 payments
  4. CABLIVI $3,957 6 payments
  5. BALFAXAR $3,409 11 payments
  6. FIBRYGA $3,114 2 payments
  7. INTERCEPT BLOOD SYSTEM FOR PLATELETS $2,267 6 payments
  8. ALINITY $726 7 payments
  9. Automated Blood Coagulation Analyzer CS-5100 $687 6 payments
  10. Yescarta $388 3 payments
  11. Other $2,764 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Octapharma USA, Inc. $64,543 31 payments

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$194,484

Medicare's payments for the services billed

Medicare patients

3,132

Average age 73

Services billed

12,811

1,647 women, 1,485 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 38%
Chronic kidney disease 37%
Diabetes 34%
Heart failure 28%
Depression 28%
Osteoporosis 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYVGART Hytrulo
  • ARGENX US, INC. $6,406
$6,406 — —
VYVGART
  • ARGENX US, INC. $6,406
$6,406 — —
Yescarta
  • Kite Pharma, Inc. $149
$149 — —
CABLIVI
  • GENZYME CORPORATION $62
$62 — —
ENJAYMO
  • GENZYME CORPORATION $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Blood Banking & Transfusion Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record